...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning
【24h】

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

机译:深静脉扫描鉴定的MPL依赖性致癌转化的新型驱动器和修饰符

获取原文
获取原文并翻译 | 示例

摘要

The single transmembrane domain (TMD) of the human thrombopoietin receptor (TpoR/ myeloproliferative leukemia [MPL] protein), encoded by exon 10 of the MPL gene, is a hotspot for somatic mutations associated with myeloproliferative neoplasms (MPNs). Approximately 6% and 14% of JAK2 V617F2 essential thrombocythemia and primary myelofibrosis patients, respectively, have "canonical" MPL exon 10 driver mutations W515L/K/R/A or S505N, which generate constitutively active receptors and consequent loss of Tpo dependence. Other "noncanonical" MPL exon 10 mutations have also been identified in patients, both alone and in combination with canonical mutations, but, in almost all cases, their functional consequences and relevance to disease are unknown. Here, we used a deep mutational scanning approach to evaluate all possible single amino acid substitutions in the human TpoR TMD for their ability to confer cytokine-independent growth in Ba/F3 cells. We identified all currently recognized driver mutations and 7 novel mutations that cause constitutive TpoR activation, and a much larger number of second-site mutations that enhance S505N-driven activation. We found examples of both of these categories in published and previously unpublished MPL exon 10 sequencing data from MPN patients, demonstrating that some, if not all, of the new mutations reported here represent likely drivers or modifiers of myeloproliferative disease.
机译:通过MPL基因的外显子10编码的人血小板素受体(TPOR / MYPHIERIFERAPEAL [MPL]蛋白)的单次跨膜结构域(TMD)是与肌酚植物肿瘤(MPN)相关的体细胞突变的热点。约6%和14%的JAK2 V617F2基本血小板血症和原发性髓体患者的患者分别具有“规范”MPL外显子10驱动突变W515L / K / R / A或S505N,其产生组成型活性受体并随之而来的TPO依赖性。其他“非甘露吞噬”的MPL外显子10突变也已在患者中均鉴定在均单独和与规范突变结合,但在几乎所有情况下,它们的功能后果和与疾病的相关性未知。在这里,我们使用深度突变扫描方法来评估人类TPOR TMD中的所有可能的单个氨基酸取代,以便它们在BA / F3细胞中赋予细胞因子的生长。我们鉴定了所有目前认可的驾驶员突变和具有组成型TPOR激活的7个新突变,以及增加了增加S505N驱动激活的更大量的第二位点突变。我们发现了来自MPN患者的发布和以前未发表的MPL外显子10测序数据中的这两个类别的例子,证明这里报告的一些新的突变可能代表野生植物疾病的可能司机或修饰剂。

著录项

  • 来源
  • 作者单位

    Walter &

    Eliza Hall Inst Med Res 1G Royal Parade Parkville Vic 3052 Australia;

    Walter &

    Eliza Hall Inst Med Res 1G Royal Parade Parkville Vic 3052 Australia;

    Univ Queensland Diamantina Inst Woolloongabba Qld Australia;

    Azienda Osped Univ Careggi CRIMM Dipartimento Med Sperimentale &

    Clin Florence Italy;

    Fdn Ist Ricovero &

    Cura Carattere Sci IRCCS Dept Hematol Oncol Unita Operat Complessa UOC Ematol;

    Fdn Ist Ricovero &

    Cura Carattere Sci IRCCS Dept Hematol Oncol Unita Operat Complessa UOC Ematol;

    Walter &

    Eliza Hall Inst Med Res 1G Royal Parade Parkville Vic 3052 Australia;

    Univ Queensland Diamantina Inst Woolloongabba Qld Australia;

    Walter &

    Eliza Hall Inst Med Res 1G Royal Parade Parkville Vic 3052 Australia;

    Fdn Ist Ricovero &

    Cura Carattere Sci IRCCS Dept Hematol Oncol Unita Operat Complessa UOC Ematol;

    Azienda Osped Univ Careggi CRIMM Dipartimento Med Sperimentale &

    Clin Florence Italy;

    Univ Queensland Diamantina Inst Woolloongabba Qld Australia;

    Walter &

    Eliza Hall Inst Med Res 1G Royal Parade Parkville Vic 3052 Australia;

    Walter &

    Eliza Hall Inst Med Res 1G Royal Parade Parkville Vic 3052 Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 血液及淋巴系疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号